BioStem Technologies will participate in the Symposium on Advanced Wound Care Spring meeting in Charlotte, North Carolina, from April 8-12, 2026. The company announced it will highlight its recently introduced Neox product line as part of its expanded portfolio of perinatal tissue allografts. SAWC serves as a premier gathering for wound care professionals, clinicians, and researchers, providing a platform for clinical dialogue and education.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated the company's participation reinforces its focus on advancing science and equipping clinicians with data and tools to improve patient outcomes. The expanded portfolio now offers what the company describes as the most comprehensive suite of placental and umbilical cord tissue solutions, backed by randomized clinical trials and real-world evidence. This expansion provides physicians with differentiated options based on clinical need, handling preferences, and site of care requirements.
During the conference, BioStem will host an Innovation Theater Lunch Symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence" on Thursday, April 9th, from 12:15 p.m. to 1:45 p.m. in Room 207C. The session will feature presentations by Dr. Wendy Weston, PhD, CTBS, William Marston, MD, and Herbert Slade, MD. Discussion topics will include an introduction to the newly expanded product portfolio, the science behind the company's birth tissue products, recently published results of a randomized controlled trial on diabetic foot ulcers, and practical guidance on incorporating these therapies into clinical practice. The session will conclude with a live question-and-answer period.
BioStem will also present a scientific poster, numbered LR-020, available for viewing in Exhibit Hall 1C. The company's booth will be open during specific exhibit hours: Thursday, April 9th from 5:30 PM to 7:30 PM EST, Friday, April 10th from 11:30 AM to 2:00 PM EST, and Saturday, April 11th from 11:30 AM to 2:00 PM EST. The company's participation demonstrates its continued investment in clinical research and medical education as it works to expand access to advanced healing technologies across various care settings.
The implications of BioStem's presentation at SAWC extend to multiple stakeholders in healthcare. For wound care professionals attending the symposium, the company's expanded portfolio offers new clinical options supported by evidence from randomized trials and real-world applications. The inclusion of the Neox product line provides additional tissue format capabilities that could address specific patient needs and procedural requirements. For the regenerative medicine industry, BioStem's focus on perinatal tissue allografts backed by clinical research contributes to the growing body of evidence supporting these advanced therapies.
BioStem Technologies operates with quality management systems and standard operating procedures reviewed and accredited by the American Association of Tissue Banks, established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. The company's portfolio includes its Neox, Clarix, VENDAJE and American Amnion product lines. Additional information about the company is available through its website at https://www.biostemtechnologies.com.
